Abstract
Purpose
The current study evaluated the in vitro activities of ceftolozane/tazobactam (C/T), imipenem/relebactam (IMI/REL), and comparators against recent (2017–2021) clinical isolates of gram-negative bacilli from two countries in southern Europe.
Methods
Nine clinical laboratories (two in Greece; seven in Italy) each collected up to 250 consecutive gram-negative isolates per year from lower respiratory tract, intraabdominal, urinary tract, and bloodstream infection samples. MICs were determined by the CLSI broth microdilution method and interpreted using 2022 EUCAST breakpoints. β-lactamase genes were identified in select β-lactam-nonsusceptible isolate subsets.
Results
C/T inhibited the growth of 85–87% of Enterobacterales and 94–96% of ESBL-positive non-CRE NME (non-Morganellaceae Enterobacterales) isolates from both countries. IMI/REL inhibited 95–98% of NME, 100% of ESBL-positive non-CRE NME, and 98–99% of KPC-positive NME isolates from both countries. Country-specific differences in percent susceptible values for C/T, IMI/REL, meropenem, piperacillin/tazobactam, levofloxacin, and amikacin were more pronounced for Pseudomonas aeruginosa than Enterobacterales. C/T and IMI/REL both inhibited 84% of P. aeruginosa isolates from Greece and 91–92% of isolates from Italy. MBL rates were estimated as 4% of Enterobacterales and 10% of P. aeruginosa isolates from Greece compared to 1% of Enterobacterales and 3% of P. aeruginosa isolates from Italy. KPC rates among Enterobacterales isolates were similar in both countries (7–8%). OXA-48-like enzymes were only identified in Enterobacterales isolates from Italy (1%) while GES carbapenemase genes were only identified in P. aeruginosa isolates from Italy (2%).
Conclusion
We conclude that C/T and IMI/REL may provide viable treatment options for many patients from Greece and Italy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Enterobacterales and Pseudomonas aeruginosa are the most frequent gram-negative pathogens causing serious infections. Resistance to first-line agents used to treat serious gram-negative infections (β-lactams, including carbapenems, and fluoroquinolones) is a global concern and is increasing with time [1,2,3]. The prevalence of antimicrobial resistance among gram-negative bacilli has been shown to vary by global region and within global regions [1,2,3]. In Europe, antimicrobial resistance is higher in southern and eastern countries than northern and western countries [3,4,5,6,7,8]. Structured surveillance initiatives are important for tracking resistance changes locally, regionally, and globally, and support therapeutic and public health policy revision and new drug development. Documenting the utility of newer β-lactam/β-lactamase inhibitor combination agents such as ceftolozane/tazobactam (C/T) and imipenem/relebactam (IMI/REL) in specific countries in global regions with elevated resistance rates to first-line anti-gram-negative therapies (e.g., southern Europe) is universally informative.
C/T is an antipseudomonal cephalosporin/β-lactamase inhibitor combination that is also active against most ESBL-positive Enterobacterales [9]. C/T is approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of complicated urinary tract infection, complicated intraabdominal infection, and hospital-acquired and ventilator-associated bacterial pneumonia (HAP and VAP). IMI/REL is a combination of imipenem/cilastatin with relebactam, a non-β-lactam diazaabicyclooctane (DBO) inhibitor of class A (ESBL, KPC) and C (AmpC) β-lactamases [4, 9]. IMI/REL is inactive against MBL-, OXA-48-like-, and GES-producing isolates of gram-negative bacilli [4, 9]. IMI/REL is approved by the EMA and the FDA for HAP and VAP, bacteremia associated with HAP and VAP (EMA only), and infections due to aerobic gram-negative bacilli in adults with limited treatment options (e.g., complicated urinary tract infection, complicated intraabdominal infection).
Previous publication of country-specific in vitro susceptibility testing data for C/T and/or IMI/REL against surveillance isolates of gram-negative bacilli causing patient infections in Greece and Italy is very limited [7, 10, 11]. We evaluated the activity of these two agents and relevant comparators against clinical isolates of gram-negative bacilli collected by clinical laboratories in Greece and Italy as part of the Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program from 2017 to 2021.
Methods
Bacterial isolates
Two clinical laboratories in Greece and seven clinical laboratories in Italy participated in the SMART global surveillance program from 2017 to 2021. Each laboratory collected isolates from lower respiratory tract infections (100 isolates/year), intraabdominal infections (75 isolates in 2017 and 50 isolates/year in 2018–2021), urinary tract infections (75 isolates in 2017 and 50 isolates/year in 2018–2021), and bloodstream infections (50 isolates/year in 2018–2021 only). All isolates were shipped to a central laboratory (IHMA, Monthey, Switzerland). Species identification was confirmed using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (Bruker Daltonics, Billerica, MA, USA) by the central laboratory. One isolate per patient per species per year is accepted by the SMART global surveillance program.
Antimicrobial susceptibility testing
MICs were determined by the CLSI reference broth microdilution method [12, 13]. Custom-made dehydrated broth microdilution panels manufactured by TREK Diagnostic Systems (Thermo Fisher Scientific, Oakwood Village, OH, USA) were used in 2017 and broth microdilution panels prepared at IHMA in 2018–2021. MICs were interpreted by 2022 EUCAST breakpoints [14]. EUCAST does not publish breakpoints for IMI/REL for Morganellaceae (Proteus, Providencia, and Morganella spp.) [14]. Imipenem has intrinsically low activity against Morganellaceae [14] by a mechanism independent of β-lactamase production [13]. Relebactam does not improve the activity of imipenem against Morganellaceae. Therefore, we only analyzed IMI/REL susceptibility for non-Morganellaceae Enterobacterales (NME) isolates. An ESBL-positive non-CRE (carbapenem-resistant Enterobacterales) phenotype was defined as an isolate of Escherichia coli, Klebsiella oxytoca, and Klebsiella pneumoniae testing with a ceftriaxone MIC ≥2 mg/L and an ertapenem MIC ≤0.5 mg/L.
β-lactamase gene detection
Isolates meeting the following phenotypic criteria were screened for β-lactamase genes: NME isolates (excluding Serratia spp.) testing with imipenem or imipenem/relebactam MIC values of ≥2 mg/L and P. aeruginosa isolates testing with imipenem or imipenem/relebactam MIC values of ≥4 mg/L collected in 2017–2021; NME and Serratia spp. isolates testing with ertapenem MIC values of ≥1 mg/L collected in 2017–2018 only; isolates of Serratia spp. testing with imipenem MIC values of ≥4 mg/L collected in 2017–2018; and Enterobacterales and P. aeruginosa isolates testing with ceftolozane/tazobactam MIC values of ≥4 mg/L and ≥8 mg/L, respectively, collected in 2017–2021. Published multiplex PCR assays were used to screen for the following β-lactamase genes: ESBLs (CTX-M, GES, PER, SHV, TEM, VEB); acquired AmpC β-lactamases (ACC, ACT, CMY, DHA, FOX, MIR, MOX) and the chromosomal AmpC intrinsic to P. aeruginosa (PDC, Pseudomonas-derived cephalosporinase); serine carbapenemases (GES, KPC, OXA-48-like [Enterobacterales], OXA-24-like [P. aeruginosa]); and metallo-β-lactamases (MBLs) (GIM, IMP, NDM, SPM, VIM) [15, 16]. All detected genes encoding carbapenemases, ESBLs, and PDC were amplified using gene-flanking primers and sequenced (Sanger). For P. aeruginosa collected in 2020 and 2021 only, isolates were characterized by short-read whole-genome sequencing (Illumina Hiseq 2×150 bp reads) to a targeted coverage depth of 100× [17] and analyzed using the CLC Genomics Workbench (Qiagen). The Resfinder database was used to detect β-lactamase genes [18]. Among 5332 collected Enterobacterales and 1094 P. aeruginosa, 16 and 8 isolates, respectively, were not available for molecular characterization and were not included in the denominators for carbapenemase rate calculations. Of these, six and four isolates, respectively, would have qualified for molecular characterization. Per SMART protocol for Enterobacterales isolates collected in 2021, a representative sample of approximately 95% of isolates meeting the criteria for molecular characterization was characterized. Accordingly, of the 171 isolates that met the testing criteria and were available for molecular characterization, eight randomly selected isolates were not characterized. Per SMART protocol for P. aeruginosa isolates collected in 2020 and 2021, a representative sample of approximately 75% of isolates meeting the criteria for molecular characterization were characterized (26 randomly selected isolates of 107 qualified isolates were not characterized). For each clinical laboratory, the percentage of qualified isolates collected in 2020 and 2021 that was not characterized was considered when calculating estimated carbapenemase rates.
Results and discussion
C/T inhibited 85–87% of all collected Enterobacterales and 94–96% of ESBL-positive non-CRE NME isolates from Greece and Italy (Table 1). Our current results for C/T agree closely with a single previous report for clinical isolates of Enterobacterales collected between 2012 and 2018 in both Greece (89% susceptible; n=1039) and Italy (86%; n=3881) [7]. Only meropenem and amikacin showed higher activity (by 2–7 percentage points) than C/T against all Enterobacterales isolates. In the current study, the majority of molecularly characterized C/T-resistant Enterobacterales isolates (72%, 564/785) from both countries carried a serine carbapenemase or MBL gene. KPCs were the most common carbapenemase gene identified in Enterobacterales isolates from both Greece (7.2%) and Italy (7.9%) confirming earlier reports [4, 5]. MBL genes were identified in 4.3% of Enterobacterales isolates from Greece and 1.2% of isolates from Italy. OXA-48-like enzymes were only identified in Enterobacterales isolates from Italy (1.4%) (Table 2).
IMI/REL inhibited 95–98% of all NME, 100% of ESBL-positive non-CRE NME, and 98–99% of KPC-positive NME isolates from Greece and Italy (Table 1). IMI/REL was more active than meropenem (87–89%), ertapenem (85–86%), amikacin (88–91%), and colistin (89%) against NME, while percent susceptible values for cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam, and levofloxacin were <80%. Levofloxacin was the least active agent tested against all Enterobacterales, NME, and ESBL-positive non-CRE NME isolates in both Greece and Italy. Less than 25% of ESBL-positive non-CRE NME isolates were levofloxacin-susceptible and 64–68% of ESBL-positive non-CRE NME isolates were piperacillin/tazobactam-susceptible. MBL genes were identified in 4.9% of NME isolates from Greece and 1.3% of NME from Italy and accounted for most IMI/REL-resistant NME isolates from both countries (81%, 99/122) confirming results from an earlier study of this resistance phenotype [4]. Twelve of 56 NME isolates from Italy that carried an OXA-48-like enzyme (MBL-negative) were also IMI/REL-resistant.
Country-specific differences in percent susceptible values for C/T, IMI/REL, meropenem, piperacillin/tazobactam, levofloxacin, and amikacin were more pronounced for P. aeruginosa than Enterobacterales (Table 1). C/T and IMI/REL both inhibited 84% of all collected P. aeruginosa isolates from Greece and 91–92% of P. aeruginosa from Italy. Our results agree closely with those previously reported by Sader et al. for C/T tested against clinical isolates of P. aeruginosa collected between 2012 and 2018 in both Greece (81% susceptible; n=284) and Italy (93%; n=881) [7]. In the current study, MBL genes were identified in 10.2% of P. aeruginosa isolates from Greece compared to 2.7% of P. aeruginosa isolates from Italy (Table 2). GES carbapenemase genes were only identified in P. aeruginosa isolates from Italy (1.7% of isolates). MBL or GES genes were identified in 63% (17/27) of characterized C/T-resistant and 68% (17/25) of characterized IMI/REL-resistant P. aeruginosa isolates from Greece and 53% (36/68) of characterized C/T-resistant and 51% (37/73) of characterized IMI/REL-resistant P. aeruginosa isolates from Italy. Elevated PDC expression (in combination with OprD deficiency for IMI/REL) may account for some of the carbapenemase-negative C/T-resistant and IMI/REL-resistant isolates [19]. C/T inhibited 13.8% (4/29) of IMI/REL-resistant (MIC >2 mg/L) P. aeruginosa, and IMI/REL inhibited 16.7% (5/30) of C/T-resistant (MIC >4 mg/L) P. aeruginosa from Greece, compared with C/T inhibition of 30.8% (24/78) of IMI/REL-resistant P. aeruginosa and IMI/REL inhibition of 25.0% (18/72) of C/T-resistant P. aeruginosa from Italy.
Colistin (>99% susceptible) was the agent with the highest percent susceptible value for P. aeruginosa from both Greece and Italy, while only 71–81% of isolates were susceptible to meropenem, cefepime, ceftazidime, and piperacillin/tazobactam. Meropenem percent susceptible values for P. aeruginosa isolates from both Greece and Italy agreed with previous studies reporting carbapenem-resistant P. aeruginosa rates in southern and eastern Europe [4, 5]. Less than 50% of meropenem-resistant and other β-lactam-resistant isolate subsets of P. aeruginosa were levofloxacin-susceptible. C/T, IMI/REL, and amikacin also demonstrated limited activity (<40% susceptible) against meropenem-, cefepime, ceftazidime-, and piperacillin/tazobactam-resistant isolates from Greece. In contrast, against P. aeruginosa isolates from Italy, both C/T and IMI/REL retained activity against 70–74% of ceftazidime- and piperacillin/tazobactam-resistant isolates, while 53% and 36% of meropenem-resistant isolates were C/T-susceptible and IMI/REL-susceptible, respectively.
In considering the colistin and amikacin data, it is important to note that given the limitations associated with colistin and aminoglycoside use in treating gram-negative infections, EUCAST only publishes bracketed colistin, amikacin (systemic infections), and gentamicin (systemic infections) susceptible and resistant MIC breakpoints with a warning against the use of any of these agents without additional therapeutic measures [14, 20]. Similarly, CLSI does not publish a susceptible MIC breakpoint for colistin for any gram-negative pathogen [13].
In conclusion, despite noteworthy carbapenemase gene carriage among isolates of Enterobacterales and P. aeruginosa from both Greece and Italy, recent (2017–2021) clinical isolates of NME collected in Greece and Italy were highly susceptible (≥95%) to IMI/REL; susceptibility of Enterobacterales to C/T was approximately 10% lower (85–86%). P. aeruginosa collected in Greece were 7–8% less susceptible to both C/T and IMI/REL (84%) than isolates from Italy (91–92%) due to higher MBL carriage in isolates from that country. Geographic differences in β-lactamase/carbapenemase prevalence and other β-lactam resistance mechanisms are well established to affect the in vitro activities of currently available β-lactams and β-lactam/β-lactamase inhibitor combinations, including C/T and IMI/REL [2, 21, 22]. Based on our in vitro data, C/T and IMI/REL remain active against the majority of isolates Enterobacterales and P. aeruginosa from both Greece and Italy and may be important treatment options for patients in these two countries with infections caused by gram-negative pathogens.
Data availability
Data is available upon reasonable request.
References
Bonomo RA, Burd EM, Conly J et al (2018) Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 66(8):1290–1297
Lob SH, Hoban DJ, Young K et al (2018) Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016. J Glob Antimicrob Resist 15:12–19
Castanheira M, Deshpande L, Mendes RE et al (2019) Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program. Open Forum Infect Dis 6(Suppl 1):S23–S33
Lob SH, Karlowsky JA, Young K et al (2020) In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART surveillance Europe 2015-2017. J Med Microbiol 69(2):207–217
Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF (2020) Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-2017. J Antimicrob Chemother 75(5):1165–1173
Karlowsky JA, Lob SH, DeRyke CA et al (2022) Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019. Int J Antimicrob Agents 59(3):106535
Sader HS, Carvalhaes CG, Duncan LR et al (2020) Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. J Antimicrob Chemother 75(10):2907–2913
European Centre for Disease Prevention and Control (ECDC) (2022) Antimicrobial resistance surveillance in Europe 2022; 2020 data. ECDC, Stockholm, Sweden https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data [accessed 4 March 2023]
Yahav D, Giske CG, Grāmatniece A et al (2021) New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev 34(1):e00115–e00120
Bianco G, Boattini M, Comini S et al (2022) Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes. J Chemother 34(5):302–310
Giani T, Arena F, Pollini S et al (2018) Italian nationwide survey of Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother 73(3):664–671
(2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—11th edition: M07. CLSI (Clinical and Laboratory Standards Institute)
(2022) Performance standards for antimicrobial susceptibility testing—32nd edn: M100. CLSI (Clinical and Laboratory Standards Institute)
(2022) EUCAST breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. Available at http://www.eucast.org/clinical_breakpoints/. Accessed 30 Dec 2022
Lob SH, Biedenbach DJ, Badal RE et al (2015) Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013. J Glob Antimicrob Resist 3(3):190–197
Nichols WW, de Jonge BLM, Kazmierczak KM et al (2016) In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60(8):4743–4749
Estabrook M, Kazmierczak KM, Wise M et al (2021) Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017. J Glob Antimicrob Resist 24:316–320
Bortolaia V, Kaas RS, Ruppe E et al (2020) ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother 75(12):3491–3500
Karlowsky JA, Lob SH, Akrich B et al (2023) In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in western Europe: SMART 2018-20. JAC Antimicrob Resist 5(1):dlad003
(2021) EUCAST breakpoints in brackets. Available at http://www.eucast.org/clinical_breakpoints_and_dosing/breakpoints_in_brackets . Accessed 30 Dec 2022
Karlowsky JA, Lob SH, Young K et al (2018) Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016. J Glob Antimicrob Resist 15:140–147
Lob SH, Hawser SP, Siddiqui F et al (2023) Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland–SMART 2017-2020. Eur J Clin Microbiol Infect Dis 42:365–370
Acknowledgements
The authors thank all SMART global surveillance program participants for their contributions to the program.
Funding
Funding for this research, which included compensation for services related to preparing this manuscript, was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Author information
Authors and Affiliations
Contributions
JAK and SHL: conceptualization, methodology, analysis, writing—original draft. SPH and NK: investigation, writing—review and editing. FS, IA, CAD, KY, and MRM: conceptualization, methodology, writing—review and editing. DFS: conceptualization, methodology, writing—review and editing, and supervision. All authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethical approval
Not required
Competing interests
SHL, SPH, NK, and DFS work for IHMA, which receives funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA for the SMART surveillance program. JAK is a consultant to IHMA. FS, IA, CAD, KY, and MRM are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and own stock in Merck & Co., Inc., Rahway, NJ, USA. The IHMA authors and JAK do not have personal financial interests in the sponsor of this manuscript (Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA).
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Karlowsky, J.A., Lob, S.H., Hawser, S.P. et al. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021. Eur J Clin Microbiol Infect Dis 43, 1343–1348 (2024). https://doi.org/10.1007/s10096-024-04756-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-024-04756-4